Results 1 to 10 of about 1,702,455 (203)

Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA? [PDF]

Folia Medica Indonesiana, 2016
Idiopathic thrombocytopenic purpura is a autoimmune disease characterized thrombocytopenia casued by excessive platelet destruction. However, both platelet destruction and reduced thrombopoietin level are occurred in some cases. Therefore, new management
Jefri Pratama Susanto
doaj   +3 more sources

Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis

Health Technology Assessment, 2020
Background: There have been no licensed treatment options in the UK for treating thrombocytopenia in people with chronic liver disease requiring surgery.
Nigel Armstrong, Nasuh Büyükkaramikli, Hannah Penton, Rob Riemsma, Pim Wetzelaer, Vanesa Huertas Carrera, Stephanie Swift, Thea Drachen, Heike Raatz, Steve Ryder, Dhwani Shah, Titas Buksnys, Gill Worthy, Steven Duffy, Maiwenn Al, Jos Kleijnen   +15 more
doaj   +1 more source

Extreme Thrombocytosis in Refractory ITP Post-Splenectomy With Associated Fatal Thromboembolism

Clinical Pathology, 2022
Thrombopoietin (TPO)-receptor agonists have heralded a paradigm shift in the treatment of refractory immune thrombocytopenia (ITP). Reactive thrombocytosis has been described as a secondary effect of such therapies.
Rithin Nedumannil, Emma Leitinger, Surender Juneja   +2 more
doaj   +1 more source

Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia

Platelets, 2022
Impaired platelet production is a mechanism of immune thrombocytopenia (ITP). Morphological abnormalities of megakaryocytes (MKs) are sometimes observed in this disease.
Ondine Walter, Agnès Ribes, Johanne Germain, Jean-Baptiste Rieu, Thibaut Comont, Albertine Plat, Brigitte Rivière, Laureline Deluche, Lucrecia Delarue, Isabelle LeGoff, Monique Greze, Béatrice Dubourdieu, Odile Rauzy, Veronique Mansat-De Mas, Guillaume Moulis, the CARMEN investigators group.   +15 more
doaj   +1 more source

Combination of two target agonists of the thrombopoietin and thrombopoietin receptor in the treatment of elderly patients with refractory immune thrombocytopenia

Cancer Pathogenesis and Therapy, 2023
Immune thrombocytopenia (ITP) is common in the elderly. Because of the coexistence of multiple diseases, there are many reservations regarding corticosteroid use in the elderly. Thrombopoietin (TPO) and its analogs can promote platelet production, but it
Jundong Zhang, Zining Wang, Haoran Chen, Xuechun Lu   +3 more
doaj   +1 more source

Eltrombopag Use for Treatment of Thrombocytopenia in a Patient with Chronic Liver Disease and Portal Vein Thrombosis: Case Report

Case Reports in Oncology, 2020
Off-label drug use refers to drug use beyond the specifications authorized for marketing [J Med Case Rep. 2014 Dec;8(1):303]. Eltrombopag is a thrombopoietin receptor agonist that has been used in treating thrombocytopenia due to chronic liver disease ...
Sabah E. Mohamed, Mohamed A. Yassin
doaj   +1 more source

Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension

Platelets, 2022
Avatrombopag is an oral thrombopoietin receptor agonist approved for chronic immune thrombocytopenia (ITP). This is a post hoc analysis of the pivotal phase III study (NCT01438840) evaluating additional endpoints not previously described.
Hanny Al‐Samkari, Srikanth Nagalla
doaj   +1 more source

Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently

Frontiers in Cardiovascular Medicine, 2023
IntroductionThrombopoietin-receptor agonist (TPO-RAs) currently represent the state of art for treating immune thrombocytopenia. Their different molecular structures contribute to the difference in their pharmacodynamics and pharmacokinetics.
Mohamed A. Yassin, Mona Al-Rasheed, Murtadha Al-Khaboori, Mahmoud Marashi, Hani Osman, Yasser Wali, Salam Al Kindi, Faisal Alsayegh, Drew Provan   +8 more
doaj   +1 more source

Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report

Leukemia Research Reports
Patients who receive allogeneic hematopoietic stem cell transplantation (alloHSCT) are at risk for developing persistent thrombocytopenia. Here, we describe treatment with avatrombopag, a thrombopoietin receptor agonist, in a pediatric patient with ...
Emilie J. Lynch, Autumn Citta, Constance Alford, John A. Ligon, Mansi Dalal, Paul Castillo, Biljana Horn, Natalie Dotson, Giselle Moore-Higgs, Jordan Milner   +9 more
doaj   +1 more source

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience

Turkish Journal of Hematology, 2015
INTRODUCTION: OBJECTIVE: Immune thrombocytopenia (ITP) is an immune mediated disease characterized by transient or persistent decrease of the platelet count to less than 100 × 109/l.
Füsun Özdemirkıran, Bahriye Payzın, H. Demet Kiper, Sibel Kabukçu, Gülsüm Akgün Çağlıyan, Selda Kahraman, Ömür Gökmen Sevindik, Cengiz Ceylan, Gürhan Kadıköylü, Fahri Şahin, Ali Keskin, Öykü Arslan, Mehmet Ali Özcan, Gülnur Görgün, Zahit Bolaman, Filiz Büyükkeçeci, Oktay Bilgir, İnci Alacacıoğlu, Filiz Vural, Murat Tombuloğlu, Zafer Gökgöz, Güray Saydam   +21 more
doaj   +3 more sources